林羣先生在生物科技、資產管理、資本市場和公司治理等領域有近40年的經驗。他是宜蘊生醫、台睿生技和全福生技的董事長，在生物科技方面有豐富經驗。曾擔任過美時化學製藥和蓮見國際生技的高階職位。
在資本市場，他曾是麥格理資本大中國區的總裁，在2008年至2009年間成為香港上市承銷的首位。在資產管理方面，他是香港賽富高鵬私募基金的資深合夥人，也曾在荷銀投資管理、藍天投資和源泰投資擔任高階職位。
林羣先生在多家上市櫃公司擔任高階職務，包括董事長、執行長、總經理等，並擔任多家公司的董事會成員，如富邦人壽、中美冠科、晶元光電、建興電子、閎暉實業和104人力銀行。
魏寶生先生有40年工作經驗。他從經濟部駐外商務人員開始，後成財政部證券管理委員會科長，負責資產管理和外資開放。後來，擔任證券暨期貨管理委員會的國際組和證券發行組組長，對台灣資本市場法規相當熟悉。
1999年調至財政部保險司副司長，後成金管會保險局首任局長，共6年。他解決了壽險公司的利差損危機，推動了保險業海外投資和新保險商品。
2004年，成為首位以保險業獲得美國艾森豪獎金台灣得主。
2005年，加入AIG台灣，擔任董事長，協助公司併購中央產險，使AIG成為當時最大的外商。
2010年，加入凱基證券擔任董事長，成功輔導多家生技公司上市，後參與了凱基銀行的成立，致力於金融科技的發展，為台灣金融業帶來新動力。
程淑芬女士現任國泰金控投資長，負責制定國泰集團的投資和經營策略。她曾在美林環球投顧擔任董事長，負責台灣區研究部和國內金控高階管理。擁有近三十年的資本市場實務經驗，專注於金融業營運策略，並推動金融市場改革。她在銀行、證券和保險業的研究方面享有盛譽，受到國際投資人和政府的重視。
程淑芬女士積極推動國泰金控參與國際氣候變遷相關組織和倡議活動，目前擔任亞洲投資人氣候變遷聯盟主席，推動亞洲機構投資人關注氣候變遷議題。她多年來致力於企業永續發展，貢獻卓著。2019年被授予「亞洲頂尖永續超級女性」獎項，並入選「2021年全球50位資產管理頂尖女性」。2022年獲頒「台灣永續傑出人物獎」。
蔡政哲先生在資產管理、生物醫學和電子商務領域有超過20年的經驗，並創辦了多家成功企業，具豐富的管理經驗。他成立了富盛證券投顧，是安盛投資管理和先機環球投資台灣的總代理，受到金融機構和銀行的認可。
2001年，蔡政哲先生加入Hutchison-Priceline，擔任亞洲區總監，推動業務發展並在新加坡籌設了分公司。之前，他在台灣擔任飛利浦多媒體的專案負責人，負責市場開發。
在生物醫學方面，他於2016年創立了安瑞生醫，專注於細胞治療技術研發，並成為宜蘊生醫的創辦人，打造了華人生殖醫學的領先品牌。
在過去十年，他擔任了技嘉科技、遠雄人壽和佳龍科技的獨立董事，並主持各委員會，積極參與公司治理。
林庭寬先生具有十餘年的四大CPA、投資銀行、投資機構等資本市場經驗，專長為投資評估、股權評價、公司治理、資本市場運作實務、財務規劃等領域，在匯力基金成立之初即加入團隊至今。
加入匯力之前，林庭寬先生在國內PE Fund任職多年，具多樣化之股權投資及市場實務經驗，此外林庭寬先生在元大投行部門亦有多年工作經驗，成功協助多家企業於台灣資本市場掛牌或進行股權籌資，在Buy side及Sell side均有相當經驗。
林庭寬先生畢業於台灣大學會計學系，擁有台灣高考會計師(CPA)、證券分析師(CSIA)等專業執照資格。
賴雅暐小姐目前擔任匯力資本投資部協理，擁有10餘年的資本市場經驗。專長為股權投資與及企業併購規劃，包含近10年之投資銀行經驗及逾5年之私募股權投資經驗。加入匯力之前，曾於某私募基金服務，負責標的評估、併購架構規劃等。並曾於國泰證券及凱基證券服務，主導或參與超過10餘件市櫃專案，包含醫材、電子、資訊服務、零售等各產業，累積豐富之相關經驗。
賴雅暐小姐為美國伊利諾大學香檳分校會計暨財務碩士，美國伊利諾州會計師會計師考試及格。
葉育瀅小姐擁有超過10年的製藥產業與基礎研究經驗，專精於臨床試驗管理、專案評估、藥品研發專案管理、品質管理、監管事務及法規策略，並累積了豐富的跨國與跨領域實務經驗。
加入匯力資本之前，葉小姐曾服務於羅氏、第一三共及禮來等國際製藥公司，以及本國晟德大藥廠與國家衛生研究院，參與多項藥物開發專案，涵蓋癌症、代謝疾病、神經退化性疾病及腸胃疾病等領域。她對小分子藥物、生物製劑、抗體及抗體藥物複合物（ADC）的研發流程具有深厚經驗，並累積了廣泛的專業知識。
葉小姐畢業於南非開普敦大學，取得生物化學與人體生理學學士學位。
Mr. Lin has nearly 40 years of experience in biotechnology, asset management, capital markets, and corporate governance. He serves as the Chairman of NUWA Biomedical, TaiRx Biotechnology, and BRIM Biotechnology, bringing extensive expertise in biotechnology. He has held senior positions at Lotus Pharmaceutical and Hasumi International Biotech.
He was formerly the President of J.P. Morgan Securities (Taiwan) Limited and became the first underwriter for a Hong Kong IPO between 2008 and 2009. He served as a Senior Partner at Hong Kong-based SAIF Eagle Fund. He is in senior positions at ABN AMRO, Chicony Chengdu International, and 源泰 Investment.
Mr. Lin has held senior positions in multiple listed companies, including Chairman, CEO, and General Manager, and has served on the board of directors for various companies such as Fubon Life Insurance, Crown Bioscience, EPISTAR, Lite-On IT Corporation, Silitech Technology Corporation, and 104 Corporation.
Mr. Wei has 40 years of work experience. He began his career as a foreign trade officer at the Ministry of Economic Affairs, later becoming the Chief of the Securities and Exchange Commission at the Ministry of Finance, responsible for asset management and foreign investment liberalization. Subsequently, he served as the head of the International Department and Securities Issuance Department at the Securities and Futures Bureau, becoming highly knowledgeable about Taiwan's capital market regulations.
In 1999, he was appointed Deputy Director of the Insurance Bureau at the Ministry of Finance, later becoming the first Director of the Insurance Bureau at the Financial Supervisory Commission, serving for a total of 6 years. He resolved the crisis of interest rate spread losses in life insurance companies and promoted overseas investments and new insurance products in the industry.
In 2004, he became the first Taiwanese recipient of the prestigious Eisenhower Exchange Fellowships in the United States.
In 2005, he joined AIG Taiwan as Chairman, facilitating the acquisition of Central Insurance Company and making AIG the largest foreign investor at that time.
In 2010, he joined KGI Securities as Chairman, successfully guiding several biotech companies to go public. He later participated in the establishment of KGI Bank, focusing on the development of financial technology and bringing new vitality to Taiwan's financial industry.
Ms. Cheng currently serves as the Chief Investment Officer of Cathay Financial Holdings and is responsible for formulating investment and operational strategies for the Cathay Group. She previously was Chairman at Merrill Lynch Global Investment, overseeing the Taiwan research department and domestic financial management. With nearly thirty years of practical experience in the capital markets, she specializes in financial industry operational strategies and advocates for financial market reforms. She is highly respected for her research in banking, securities, and insurance industries, garnering attention from international investors and governments.
Ms. Cheng actively promotes Cathay Financial Holdings' participation in international climate change-related organizations and advocacy activities. She currently serves as the Chairperson of the Asian Investors' Climate Change Alliance, advocating for Asian institutional investors to focus on climate change issues. Over the years, she has been dedicated to corporate sustainable development, making significant contributions. In 2019, she was awarded the "Asia's Top Sustainability Superwomen" award and was named one of the "Global Top 50 Women in Asset Management" in 2021. In 2022, she was honored with the "Taiwan Outstanding Sustainable Figure Award."
Mr. Tsai has over 20 years of experience in asset management, biomedicine, and e-commerce fields, having founded multiple successful enterprises and possessing extensive management expertise. He established Capital Gateway Investments and serves as the general agent for AXA Investment Managers and Old Mutual Global Investors in Taiwan, recognized by financial institutions and banks.
In 2001, Mr. Tsai joined Hutchison-Priceline as the Director for the Asia-Pacific region, driving business development and establishing a subsidiary in Singapore. Previously, he served as the project manager for Philips Multimedia in Taiwan, overseeing market development.
In the field of biomedicine, he founded Ceres Biomedical in 2016, focusing on the research and development of cellular therapy techniques, and co-founded NUWA Biomedical, leading the development of the foremost brand in Chinese reproductive medicine.
Over the past decade, he has served as an independent director for companies such as GIGA-BYTE Technology, Farglory Life Insurance, and Super Dragon Technolog, chairing various committees and actively participating in corporate governance.
Mr. Lin has over a decade of experience in capital markets, including roles in Big Four, investment banking, and private equity. His expertise lies in investment assessment, equity valuation, corporate governance, capital market, and financial planning. He has been with Affinity since it was founded.
Prior to Affinity, Mr. Lin worked at a domestic PE Fund for several years , gaining diversified experience in equity investments and market practices. Additionally, he has several years of experience in Yuanta Securities, where he successfully assisted plenty of enterprises in Taiwan's capital markets with IPO listings and equity fundraising. He has substantial experience on both Buy side and Sell side.
Mr. Lin graduated from National Taiwan University with a degree in Accounting. In addition, he holds professional licenses as Certified Public Accountant (CPA) and Certified Securities Investment Analyst (CSIA) in Taiwan.
Ms. Lai currently serves as senior manager at Hui Li International, with over 5 years of buy-side experience in private equity investment and nearly 10 years of sell-side experience in investment banking. Before joining Hui Li International, she worked at a private equity fund, where she was responsible for target evaluation and M&A structuring. She has also worked at Cathay Securities and KGI Securities, leading or participating in more than 10 public market projects across various industries, including medical devices, electronics, information services, and retail, accumulating extensive relevant experience.
Ms. Lai holds a Master's degree in Accounting and Finance from the University of Illinois at Urbana-Champaign and is a certified public accountant in the state of Illinois.
Ms. Yeh has extensive cross-border and cross-functional expertise with over 10 years of experience in the pharmaceutical industry and foundational research, specializing in clinical trial management, project evaluation, drug development project management, quality, inspection/audit and regulatory strategy.
Prior to joining Afiinity Capital, Ms. Yeh held positions at global pharmaceutical companies, including Roche, Daiichi Sankyo, and Eli Lilly, as well as Taiwan pharmaceutical such as Center Laboratories, as well as the National Health Research Institutes. She has participated in numerous drug development projects across therapeutic areas, including oncology, metabolic disorders, neurodegenerative diseases, and gastrointestinal diseases. She brings deep experience in the development processes of small molecules, biologics, antibodies, and antibody-drug conjugates (ADCs).
Ms. Yeh received her Bachelor’s degree in Biochemistry and Human Physiology from the University of Cape Town.
楊紹云小姐是匯力資本的執行秘書，負責協調和管理公司的日常行政支持工作，並積極有效地組織各項工作流程。
Ms. Yang is the executive secretary at Hui Li International, coordinating and managing the company's daily administrative support tasks, and actively organizing various work processes efficiently and effectively.
Ms. Kuang currently serves as an assistant manager at Hui Li International. With 7 years of experiences in capital markets and financial consulting, she specializes in investment banking projects and M&A deals.
Before joining Hui Li International, she served in the transaction service department of KPMG Taiwan for 2.5 years, providing financial due diligence service for M&A and equity investment deals. The industries include manufacturing, finance, online education, electronic payment, food and fast food chains, etc. She also served in the investment banking department of IBF Securities and CTBC Securities for a total of 5 years, where she participated in IPOs of Ingentec and Thai Kin-KY, and SPOs such as Hiroca-KY and Fulgent Sun-KY.
Ms. Kuang holds a Master of Science in Banking and International Finance degree from Bayes Business School, City University of London, and a Bachelor in International Business from National Chengchi University.
匡小姐目前擔任匯力資本副理，擁有7年資本市場及財務顧問經驗，專長為企業併購及資本市場專案規劃。
加入匯力之前，曾於KPMG財務顧問部服務2年半，負責企業併購及股權投資財務盡職調查，產業含括製造、金融、線上教育、電子支付、食品及連鎖速食等。並曾於國票證券及中國信託證券之投資銀行部門合計服務5年，參與晶呈科技及泰金-KY之IPO案件，及廣華-KY、鈺齊-KY等SPO案件。
匡小姐為英國倫敦城市大學貝葉斯商學院財務金融碩士，及政治大學國際經營與貿易學士。
